EMA Authorised: Imreplys (sargramostim) — Partner Therapeutics Limited

View source ↗

Summary

The European Medicines Agency authorised Imreplys (sargramostim) for acute radiation syndrome, with Partner Therapeutics Limited as the marketing authorization …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Radiation Syndrome

Drugs mentioned

• Imreplys (sargramostim)

Snippet

Status: Authorised. Therapeutic area: Acute Radiation Syndrome. MAH: Partner Therapeutics Limited. Decision date: 21/08/2025